Does PRP work for Achilles tendon injuries? The strongest evidence says no.
For a complete rupture of the Achilles tendon, the most rigorous study available—a large, placebo-controlled trial of 230 patients—found that a PRP injection provided no benefit. At two years after the injury, patients who received PRP reported the same level of function (measured by the Achilles Tendon Total Rupture Score) as those who received a placebo injection [1]. A separate analysis of this same trial data confirmed that the probability of PRP providing a meaningful clinical improvement was less than 0.001% [4].
A broader analysis of 13 randomized trials on Achilles tendon problems (both ruptures and tendinopathy) also found no consistent benefit from PRP. While there was a temporary improvement in pain scores at three months for tendinopathy, this did not translate into better long-term function, return to sport, or patient satisfaction [3]. For ruptures specifically, PRP did not improve function, heel lift height, or calf circumference at any time point up to a year [3].
PRP shows promise as a surgical aid for rotator cuff tears.
The evidence for PRP in rotator cuff injuries is more positive, but it is used differently. Instead of a simple injection, PRP is often applied as a gel directly to the tendon-bone interface during arthroscopic repair surgery. A study of 152 patients found that those who received a PRP gel during surgery had significantly better outcomes at six months: 89% achieved favorable tendon healing on MRI compared to 54% in the control group, and the retear rate was much lower (2.2% vs. 13.1%) [2]. Patients also reported greater improvements in shoulder function and pain [2].
Laboratory research supports this finding. Studies in mice and rats show that PRP can improve the healing of the tendon-bone interface, which is the critical point of failure in rotator cuff repairs [5][6]. One study found that a PRP-loaded hydrogel promoted bone and tendon regeneration in a rat model, leading to superior repair compared to surgery alone [6]. However, not all animal studies agree; one rabbit study found that adding PRP to a surgical scaffold did not provide any additional benefit over the scaffold alone [7].
Why does PRP work for some tendon injuries but not others?
The key difference likely lies in how PRP is delivered and the type of injury. For an acute Achilles rupture, a single injection into the gap between the torn tendon ends may not be enough to influence the complex healing process [1]. In contrast, for rotator cuff surgery, the PRP gel is placed precisely at the tendon-bone interface and held in place, providing a sustained release of growth factors directly where new tissue needs to form [2][6].
The type of PRP also matters. PRP can be 'leukocyte-rich' (containing many white blood cells) or 'leukocyte-poor'. A mouse study found that leukocyte-rich PRP was better for early healing, while leukocyte-poor PRP was better for the later stages of tendon-bone healing [5]. This suggests that the optimal PRP formulation may depend on the specific phase of healing you are trying to target. Furthermore, a patient's own health can affect results; for example, high uric acid levels (hyperuricemia) can alter how tendon cells respond to PRP, potentially reducing its anti-inflammatory effects [8].
About These Sources
This answer is built on 8 peer-reviewed studies — published from 2015 to 2026, 4 from 2024 or later, 2 in Q1 journals, collectively cited 55 times — selected as the most relevant from 13 studies that passed quality screening, drawn from 76 papers retrieved from a database of over 500 million.
Sources used in this answer
Platelet-rich plasma injection for acute Achilles tendon rupture
In the largest randomized trial on this topic (n=230), PRP injection did not improve patient-reported function or quality of life two years after an acute Achilles tendon rupture compared to a placebo [1].
Arthroscopic PRP gel augmentation at the tendon-bone interface accelerates functional recovery and structural healing in rotator cuff repair: a retrospective cohort study.
In a retrospective study of 152 patients, applying a PRP gel during arthroscopic rotator cuff repair led to significantly better functional recovery, less pain, and superior tendon healing on MRI at 6 months, with a much lower retear rate (2.2% vs. 13.1%) [2].
Effectiveness of platelet-rich plasma in the treatment of Achilles tendon disease
A meta-analysis of 13 randomized trials found that PRP for Achilles tendinopathy only improved pain at 3 months, with no long-term benefit for function, tendon thickness, or return to sport; for Achilles ruptures, PRP showed no significant benefit on any key outcome [3].
Bayesian Re-analysis of Two-Year Outcomes in the Platelet-Rich Plasma in Achilles Tendon Healing 2 (PATH-2) Trial: Platelet-Rich Plasma for Achilles Tendon Rupture.
A Bayesian re-analysis of the PATH-2 trial data confirmed that the probability of PRP providing a clinically meaningful benefit for Achilles tendon rupture was less than 0.001% [6].
Effects of leukocyte-rich platelet-rich plasma and leukocyte-poor platelet-rich plasma on the healing of bone-tendon interface of rotator cuff in a mice model
In a mouse model of rotator cuff repair, leukocyte-rich PRP enhanced early healing, while leukocyte-poor PRP improved later-stage healing of the bone-tendon interface [8].
PRP-loaded hydrogel for rotator cuff repair by promoting osteogenic differentiation and tendon regeneration
A PRP-loaded hydrogel (PRP-CMCS-TA) promoted bone and tendon regeneration in a rat rotator cuff injury model, leading to superior repair compared to controls [9].
Study of bone-tendon interface healing in an animal model using a synthetic scaffold and PRP
In a rabbit model of tendon-bone repair, adding PRP to a synthetic scaffold did not provide additional biomechanical or microscopic benefits over the scaffold alone at 8 weeks [11].
Hyperuricemic PRP in tendon cells.
Hyperuricemia (high uric acid) altered the response of human tendon cells to PRP in vitro, reducing the production of certain anti-inflammatory proteins and changing the expression of extracellular matrix genes [13].
